Accord Healthcare

Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to over 70 markets around the world.
 

REPORT A SIDE EFFECT

report

GROWTH’S IN OUR NATURE

With an extensive presence in all regions of the world, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies.

Our robust product portfolio in growth-oriented therapies allows us to compete with some of the biggest portfolios in the industry, as well as helping to extend our presence into new markets.

Accord’s operations began with a strategic vision to create a global brand, supported by a commercial infrastructure that enables us to bring our high quality yet affordable products to patients around the world. We commit ourselves to challenging the unmet medical, societal and patient needs of the day.

01

TRULY MULTINATIONAL

Accord Healthcare is the international arm of Intas Pharmaceuticals Ltd., with commercial operations in more than 70 countries globally and close to 65 EMENA markets. The first Accord commercial operations in Europe were recorded in 2008 in the United Kingdom. Currently, our portfolio comprises 423 generic INNs, including 50 novel Added Value Products.

02

A COMPLETE APPROACH

Accord’s vision is to be involved in all aspects of bringing pharmaceuticals to patients. Our activities today encompass the entire pharmaceutical value chain and so create a truly integrated offering.

04

News

10-10-2018

ACCORD HEALTHCARE - THE MOST RECOGNISED COMPANY AT THE GLOBAL GENERICS & BIOSIMILAR AWARDS 2018

We are delighted to announce that Accord Healthcare was the most recognised company at the Global Generics & Biosimilar Awards 2018, having won awards for: Company of the Year and Biosimilar Initiative of the Year. 

27-07-2018

Accord Healthcare’s (Intas) Pelgraz® (pegfilgrastim) Given Green Light by CHMP

Pelgraz - a pegylated G-CSF Biosimilar, is latest addition to Accord Healthcare's established portfolio of over 30 oncology treatments across Europe